Literature DB >> 16309801

Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains.

Steven Rubin1, Jeremy Mauldin, Konstantin Chumakov, Jackie Vanderzanden, Rebecca Iskow, Kathryn Carbone.   

Abstract

The recent resurgence of mumps epidemics in many countries with ongoing vaccination programs along with evidence of antigenic diversity among mumps virus strains have recently challenged the assumption that mumps virus is serologically monotypic. To address this controversy, we sought to identify two mumps virus strains that would best represent different serotypes, should multiple serotypes exist, and assess the ability of human sera to neutralize both strains. The virus strains, Enders and Lo1, were selected based upon a phylogenetic analysis of the major target of neutralizing antibody, the viral hemagglutinin-neuraminidase (HN) protein, along with data reported by others indicating that (1) these viruses are antigenically distinct and (2) genotypically similar strains have been implicated in cases of reinfection. Our results show that of sera capable of neutralizing one of the virus strains, 90% could neutralize the other, although significant differences in neutralization titers were noted. Though the latter confirms the existence of inter-strain antigenic variability, the fact that few sera were unable to neutralize both virus strains argues against the presence of multiple serotypes. Of those sera incapable of co-neutralization, all but one had low neutralization titers (1:8), suggesting that individuals possessing low levels of neutralizing antibody may be at risk for breakthrough infections, thereby providing an explanation for cases of infection in previously infected or vaccinated individuals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309801     DOI: 10.1016/j.vaccine.2005.10.050

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Factors influencing preclinical in vivo evaluation of mumps vaccine strain immunogenicity.

Authors:  B Halassy; T Kurtović; M Brgles; M Lang Balija; D Forčić
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method.

Authors:  Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

3.  Enzyme-linked immunospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis.

Authors:  Donald R Latner; Marcia McGrew; Nobia Williams; Luis Lowe; Roniel Werman; Eli Warnock; Kathleen Gallagher; Peter Doyle; Sandra Smole; Susan Lett; Noelle Cocoros; Alfred DeMaria; Raimond Konomi; Cedric J Brown; Paul A Rota; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 4.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

5.  Guidelines for the Prevention and Control of Mumps Outbreaks in Canada.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-04

6.  Seroepidemiology of mumps in the general population of Jiangsu province, China after introduction of a one-dose measles-mumps-rubella vaccine.

Authors:  Yuanbao Liu; Ying Hu; Xiuying Deng; Zhiguo Wang; Peishan Lu; Fubao Ma; Minghao Zhou; Pei Liu; Jie Min
Journal:  Sci Rep       Date:  2015-10-01       Impact factor: 4.379

7.  Vaccine waning and mumps re-emergence in the United States.

Authors:  Joseph A Lewnard; Yonatan H Grad
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

8.  A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.

Authors:  Emma Herrera; Patricia Barcenas; Rubicela Hernández; Alfonso Méndez; Guillermo Pérez-Ishiwara; Blanca Barrón
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

9.  Immune responses to mumps vaccine in adults who were vaccinated in childhood.

Authors:  Rima Hanna-Wakim; Linda L Yasukawa; Phillip Sung; Ann M Arvin; Hayley A Gans
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

10.  Real-time reverse transcription-PCR assay for detection of mumps virus RNA in clinical specimens.

Authors:  Jennifer D Boddicker; Paul A Rota; Trisha Kreman; Andrea Wangeman; Louis Lowe; Kimberly B Hummel; Robert Thompson; William J Bellini; Michael Pentella; Lucy E Desjardin
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.